Skip to main content
. Author manuscript; available in PMC: 2022 May 15.
Published in final edited form as: Gynecol Oncol. 2020 Nov 7;160(1):285–294. doi: 10.1016/j.ygyno.2020.10.031

Fig. 5.

Fig. 5.

The addition of anti-PD-1 does not enhance CGX-1321-mediated anti-tumor effects in the ID8p53−/− model. ID8p53−/− model was initiated and treatment with 1 mg/kg CGX-1321 (oral gavage; daily), 250 μg/mouse anti-PD-1 (intraperitoneal injection; every 3 days), and vehicle/control started 10–days post-tumor challenge. (A) Omental weights (g) and (B) ascites volumes (uL) were measured at day 44. Flow cytometry analysis was performed on omentums to determine the levels of infiltrating of (C) T (CD3+) cells, (D) cytotoxic T (Tc; CD8+) cells, (E) B (B220+) cells, and (F) natural killer (NK1.1+) cells in TME.